MimoPath®Covered Ureteral Stent System NMPA Reg. No. 20253132510 BENIGN URETERAL STRICTURE ·CURATIVE INTENT STENT-FREE PATENCY The endpoint is not longer dwell time but ultimately no stent at all. Curative intent Segmental therapy Evidence base Durable post-removal patency Large-caliber covered support Three post-removal studies Improving health and quality of life

ABOUT SURGSCI SURGSCI MEDICAL LTD. SurgSci focuses on core technologies and innovative applications in minimally invasive surgery. The company has established three major technology platforms: medical-grade metal materials, polymer materials, and artificial intelligence algorithms. These platforms support two primary product lines— surgical instruments and surgical consumables. SurgSci has successfully overcome key technical challenges in high-performance medical titanium alloys, advanced piezoelectric ceramic materials, and AI-driven intelligent ultrasonic high-frequency surgical systems. As...

MimoPath®Covered Ureteral Stent System Stable support. Sustained patency. Complete treatment pathway Maintain caliber Sustained patency Priority candidates supported by clinical evidence Impacted-stone or post-URS benign ureteral stricture Etiology with the strongest post-removal evidence Short benign strictures, especially ≤2 cm The latest 101-case study favored shorter strictures Published clinical findings 85.5% 83 stone/URS cases formed the main cohort Recurrent stricture after balloon dilation or endoureterotomy Guidewire passage remains possible and renal function is worth preserving Repeated...

MimoPath®Covered Ureteral Stent System Engineering chain for curative potential The device must do more than open the ureter: it must address recoil, tissue ingrowth, migration control and eventual removal. Balloon dilation Define etiology, length and traversability Release the stenotic ring and establish initial caliber Segmental support Continuous 8/9/10 mm radial support Block ingrowth Uncoil and remove Full covering prevents Remove after tissue entering the treatment, then assess stent mesh sustained patency Four engineering features address four clinical needs Large-caliber selfexpansion...

MimoPath®Covered Ureteral Stent System Evidence of patency after removal Across cohorts of 17 to 101 patients, device-free patency after removal ranged from 35.3% to 85.5%, highlighting the value of patient selection and treatment-course management. 6 / 17 required no further treatment after removal 76.5% were stone-related; most had prior Mean dwell 14.3 months Mean follow-up after removal 10.4 months dilation/incision. In this first long-term series, 6 patients needed no further treatment after removal, informing later optimization of selection, coverage and follow-up. 71 / 83 required no further...

MimoPath®Covered Ureteral Stent System Pooled post-removal patency: ≈2/3 Across 201 patients in three studies, random-effects pooled post-removal patency was 65.3%; between-cohort differences support more precise selection and pathway optimization. Sustained patency after removal: randomeffects meta-analysis Pooled effect Outcome differences identify a clear improvement path: prioritize short benign strictures and optimize etiology, dwell time and follow-up. References [1] Avitan O, et al. Urol Int. 2022;106:482–486. DOI:10.1159/000522174 [2] Salciccia S, et al. Front Urol. 2022;2:984719. DOI:10.3389/fruro.2022.984719...

MimoPath®Covered Ureteral Stent System Start with ideal cases Evidence defines a clear starting profile: short, benign, stone-related or post-URS strictures are best suited for early validation of sustained post-removal patency. High-potential starting profile Improve the chance of success Benign stricture with guidewire passage Define etiology, length and guidewire passage preoperatively Recurrent stricture after impacted stones or URS Control infection and stone burden before treatment Cover the lesion accurately with both ends clearly visible Repeated DJ exchange; seeking to avoid or defer...

Improving Human Health and Quality of Life Email: [email protected] R&D Center: 3/F, Shunhengli Building, 118 Xin'an 3rd Rd., Bao'an District, Shenzhen Manufacturing Center: 3/F, Building 2, Runheng Electronics Factory, Liuxian 2nd Rd., Bao'an District, Shenzhen